In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Asterias Biotherapeutics is a development-stage biotechnology company pioneering the field of regenerative medicine. It focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. It is also developing human embryonic stem cell programs, including cell lines and a Phase I clinical trial in patients with acute spinal cord injury; intellectual property related to its autologous cellular immunotherapy program, including a Phase I/II clinical trial of autologous immunotherapy in patients with acute myelogenous leukemia; and non-therapeutic applications of pluripotent stem cells, such as cellular assay products for use in drug development and toxicity screening. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.

Tularik engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company is considered a pioneer in the field of cell signaling and the control of gene expression. The company is focused primarily of three main areas; inflammation, metabolic diseases and oncology. Tularik was founded by David Goeddel along with Steve McKnight and Robert Tjian in 1991. The company was acquired by Amgen for US$ 1.3 billion in 2004.

Taizhou Medical City Guokehua Biomedical Technology Co., Ltd., established on 2016-09-27, Business scope includes technology development of biomedical materials,transfer,consult,Promotion services and related product development;Science and Technology Information Consulting Services;Technology project agency service;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export);food production,Sales,medicine(traditional Chinese medicine,chemical medicine,biological drug),one type,R&D and technical consultation of Class II medical devices,technology transfer,Technical extension services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Biochemical product technology research and development;Chemical product sales(No licensed chemical products);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Fluidigm Corporation is a biotechnology research agency that helps in improving health.

Ocimum Biosolutions is a leading integrated global genomics company providing GLP-compliant microarray services, comprehensive genomic reference databases, life science lab information management solutions and essential research consumables. Majority of the top 25 pharmaceutical companies, leading research institutes and emerging biotech companies worldwide have chosen us as their preferred outsourcing partner and utilize our expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers. There solutions span across key priority areas including BioPharmaceutical, Diagnostics, Agriculture, Food & Nutrition. Diverse research and development efforts in such key areas have benefited from our unique range of integrated services.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Geron is a biotechnology company that specializes in developing blood cancer treatments for hematologic malignancies. The company's Imetelstat, an investigational first-in-class telomerase inhibitor, harnesses Nobel Prize-winning science in a treatment that may change the underlying course of these diseases. Geron was established in 1990 and is headquartered in Foster City, California.

Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD.

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. It offers specialty pharmacy and laboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

Nanjing Qizhen Genetic Engineering Co., Ltd., established on 2018-05-10, Business scope includes gene technology,Biotechnology,medical technology,Technological Development of Agricultural Technology,technical consulting,technology transfer,Technical Services;Biological Products Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Cytovia, Inc. provides biomedical research services. The firm discovers and develops therapeutics and products to assist physicians in curing cancer and certain degenerative diseases. The company was founded by Daniel Teper and is headquartered in San Diego, CA.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Guangdong Qianhui Biotechnology Co., Ltd., established on 2011-03-22, Business scope includes general business items:Biomedical Technology Development,Technical Services,technical consulting,technology transfer.,The licensing program is:none